PMID- 22523565
OWN - NLM
STAT- MEDLINE
DCOM- 20120803
LR  - 20211021
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 7
IP  - 4
DP  - 2012
TI  - Ablation of proliferating cells in the CNS exacerbates motor neuron disease 
      caused by mutant superoxide dismutase.
PG  - e34932
LID - 10.1371/journal.pone.0034932 [doi]
LID - e34932
AB  - Proliferation of glia and immune cells is a common pathological feature of many 
      neurodegenerative diseases including amyotrophic lateral sclerosis (ALS). Here, 
      to investigate the role of proliferating cells in motor neuron disease, 
      SOD1(G93A) transgenic mice were treated intracerebroventicularly (i.c.v.) with 
      the anti-mitotic drug cytosine arabinoside (Ara-C). I.c.v. delivery of Ara-C 
      accelerated disease progression in SOD1(G93A) mouse model of ALS. Ara-C treatment 
      caused substantial decreases in the number of microglia, NG2+ progenitors, Olig2+ 
      cells and CD3+ T cells in the lumbar spinal cord of symptomatic SOD1(G93A) 
      transgenic mice. Exacerbation of disease was also associated with significant 
      alterations in the expression inflammatory molecules IL-1beta, IL-6, TGF-beta and the 
      growth factor IGF-1.
FAU - Audet, Jean-Nicolas
AU  - Audet JN
AD  - Research Centre of CHUQ, Department of Psychiatry and Neurosciences, Laval 
      University, Quebec, Canada.
FAU - Gowing, Genevieve
AU  - Gowing G
FAU - Paradis, Renee
AU  - Paradis R
FAU - Soucy, Genevieve
AU  - Soucy G
FAU - Julien, Jean-Pierre
AU  - Julien JP
LA  - eng
GR  - Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120416
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Interleukin-6)
RN  - 0 (Transforming Growth Factor beta)
RN  - 04079A1RDZ (Cytarabine)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
SB  - IM
MH  - Amyotrophic Lateral Sclerosis/pathology
MH  - Animals
MH  - Cell Proliferation/drug effects
MH  - Cytarabine/pharmacology
MH  - Disease Models, Animal
MH  - Disease Progression
MH  - Humans
MH  - Insulin-Like Growth Factor I/metabolism
MH  - Interleukin-6/metabolism
MH  - Mice
MH  - Mice, Transgenic
MH  - Microglia/drug effects
MH  - Motor Neuron Disease/*complications
MH  - Superoxide Dismutase/*genetics
MH  - Transforming Growth Factor beta/metabolism
PMC - PMC3327706
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2012/04/24 06:00
MHDA- 2012/08/04 06:00
PMCR- 2012/04/16
CRDT- 2012/04/24 06:00
PHST- 2011/12/09 00:00 [received]
PHST- 2012/03/06 00:00 [accepted]
PHST- 2012/04/24 06:00 [entrez]
PHST- 2012/04/24 06:00 [pubmed]
PHST- 2012/08/04 06:00 [medline]
PHST- 2012/04/16 00:00 [pmc-release]
AID - PONE-D-11-24669 [pii]
AID - 10.1371/journal.pone.0034932 [doi]
PST - ppublish
SO  - PLoS One. 2012;7(4):e34932. doi: 10.1371/journal.pone.0034932. Epub 2012 Apr 16.